respectively. A total of 35 pts had local recurrence, and 50 pts had dis-
tant metastasis. A total of 14 pts had died. In relation to side effects, 3 pts had localized moist desquamation, skin pigmentation was observed in 4 pts, and telangiectasias were observed in 7 pts. Breast fibrosis was pre-
sent in 2% of pts. Cosmesis results were considered good or excellent in 82% of pts.

Conclusions: LDR-BQT as a boost-treatment modality achieved high long term local control, overall survival and disease free survival in pts with pres-
serving-breast cancer stage I and II, without late effects and good/excellent cosmesis results.

30 oral
Long term results of high-dose rate (HDR) brachytherapy (BQT) boost in preserving-breast cancer patients (pts): The experience of Radiation Oncology Medical Institute (IMOR) of Barcelona.

I. Henriquez, B. Guix, J.T. Tello, A. Martinez, J.A. Lejarcegui, F. Fines tres IMOR, Radiation Oncology, Barcelona, Spain

Introduction: Stage I and II preserving-breast cancer pts with histological risk factors are treated with external beam radiotherapy (EBR) and BQT boost with HDR. The aim of the study was to analyze long term results of a prospective group of stage I and II breast cancer patients, in terms of local control, survival, as well as cosmesis and side effects.

Material and methods: Between December 1991 and December 2000, 294 pts were treated with conservative surgery, and EBR 50.4 Gy/28 fr over 5.5 wks, followed by BQT boost with HDR-BQT. All pts had infiltrating ductal carcinoma of the breast, tumoral size < 4 cm, with or without intraductal component. After 2-3 weeks of completion EBR, HDR-BQT total dose was given depend on histological risk factors. Pts without intraductal compo-
ent or surgical margin less than 1 cm received 18 Gy with 200-250 cGy/fr in 2-3 fr per day in 3-5 days (group 1). Pts with intraductal component or surgical margin greater than 1 cm received 20-22 Gy with the same frac-
tionation (group 2). HDR-BQT boost total doses were calculated following the lineal quadractic model to be equivalent to LDR in terms of early/late effects. The dose was prescribed at the isodose of 95% of the basal dose rate with geometric optimization of dose distribution. Pts within BQT treat-
ment were in an outpatient basis. All pts completed treatment, and no pt was lost to follow-up. Pts were stratified in 3 groups:

1. Patients with a clinical margin of 1-3 mm.
2. Patients with a clinical margin > 3 mm.
3. Patients with a histological margin > 3 mm.

Results: A 7 year overall survival was 89.2%, the freedom from local recurrence 82.7%, survival without metastases 84.9% and the disease free survival was 72.3%. Patients were followed for a median of 7 years (range 4-12 months). The median follow-up of 70 months (range 4 and 12 months), actuarial overall survival at 9 yrs HDR-BQT boost was 99%, disease-free survival was 88% and local control was 91%. A total of 15 pts had local recurrence, 11 pts had distant metastasis, and 3 pts had died. In relation to side effects, 3 pts had localized moist desquamation, 8 pts skin pigmentation, and 5 pts telangiectasias. Breast fibrosis was present in 1.8% of pts. Cosmesis results were considered good or excellent in 96% of pts.

Conclusions: HDR-BQT as an effective modality for treatment of tumor bed boost in preserving-breast cancer, because it achieved a high long-term local control and survival in stage I and II breast cancer pts. The outpatient basis modality, radioprotection to staff, and the better radiobiological effects of HDR on tissue than LDR-BQT, are some of the important aspects to be considered when HDR-BQT is used.

31 oral
Brachytherapy boost parameters and local recurrence in breast cancer patients treated with conservative surgery and radiotherapy

M. Mahler1, F. Campagna2, E. Mouret-Fournier3, R. Dendael4, J. Vilcoq5, A. Fourquet6

1Istituto Cure, Paris, France
2Academic Medical Center/University of Amsterdam, Radiotherapy, Amsterdam, The Netherlands
3The Netherlands Cancer Institute / Antoni van Leeuwenhoek Huis, Radiotherapy, Amsterdam, The Netherlands

Purpose: the aim of this study was to examine the relationship between local recurrence of breast cancer and the technical aspects of low dose rate brachytherapy boost in patients undergoing treatment with conservative surgery and post-operative radiotherapy. Parameters analyzed included the number of lines/planes implanted, implant volume, 192Ir activity employed, total length of 192Ir used, implant duration, dose delivered and localized. Doses of implant within the treated breast. All clinical parameters were also analyzed for significance to local recurrence.

Methods & materials: we present a retrospective series of 290 breast cancer pa-
cients treated in Institut Cure between 1982-1995, whose treatment incorporated a brachytherapy boost to the tumor bed. All patients had an iodium 192 interstitial implant following post-operative external beam radio-
therapy (52.2 Gy, 29 fractions of 180Gy). Patients were selected for treat-
ment with brachytherapy boost because of invasive tumor at the margin of excision (18.9%), DCIS involved margins (24.5%), invasive tumor within 3mm of the resection margin (31.4%), or the presence of a combination of factors which increase risk of local recurrence, such as tumor size, tumor grade, axillary nodes and/or negative oestrogen receptors in the remaining 25.2% of patients whose margin of excision was greater than 3mm. The median age of the study group was 52 years with a median clinical tumor dimension at presentation of 2cm. The median number of radioactive lines implanted was 4, median total length of 20cms, delivering a median of 20 Gy in accordance with the Paris dosimetry system.

Results: at median follow-up of 80 months, the 7 year overall survival was 89.2%, the freedom from local recurrence 82.7%, survival without metas-
tases 84.9% and the disease free survival was 72.3%. Factors found on multivariate analysis to be statistically significant in predicting for local recurrence were brachytherapy boost time (P < 0.0002) and the Paris dosimetry system.

Conclusion: brachytherapy boost treatment was found to have a critical threshold of 16.500 mm2 and the parameters, isodose length and thickness were also found to be significant. The only reliable method of obtaining this critical volume of 16.500 mm2 in interstitial breast brachytherapy is with a two plane implant. Although there was no excess of breast cancer recur-
genesis for upper inner quadrant and axillary tail,但是在 this study the conformity to a defined planning target volume (PTV) for different implant geometries and the effect of dose normalization were investigated. Using clinical data an estimation of the risk for fibrosis for the different implants was assessed.

Material and Methods: The dose distributions of four implant geometries were compared for a PTV of 48 cm3. Implants #1 and #2 had linear sources arranged in a triangular pattern of equal lengths and lengths adapted to the shape of the PTV. Implants #3 and #4 were squared pattern arranged implants with linear sources and a stepping source with geometric opti-
mized dwell times. The active lengths were adapted to the shape of the PTV. Using implant #4 for PTVs of different volumes, the reference dose (RD) was normalized to 85% and 91% of the mean central dose (MCD) respecting full coverage of the PTV. Normalization to a higher isodose than the conventional 85% of the MCD was chosen to improve dose uniformity. Volumetric parameters were derived from cumulative dosee-volume his-
tograms and used to estimate the risk for moderate to severe fibrosis.

Results. Comparing implants #2, #3, and #4 with #1, the treated volume (V(100)) encompassed by the reference isodose was reduced by 22%, 35%, and 37%, respectively. The conformation number increased being 0.54 for each of implants #7, and 0.7 for #1. #2 and #4. The V(100) was not different when comparing dose normalization to 91% and 85% of the MCD. The average reduction of the volumes receiving a dose of at least 125% (V(125)) of the RD when the dose was normalized to 91% compared to 85% of the MCD was 18%. Comparing implant #1 with #4, the risk to develop moderate to severe fibrosis was decreased from 60% to 45%. Unfortunately there is no clinical data to assess the effect of a more uniform dose distribution on cosmesis.

Conclusion. A conformal treatment to a PTV could be best achieved with a geometrically optimized stepping source plan with needles arranged in a squared pattern. Reduction of high dose volumes within the implant was
obtained by normalizing the RD to 91% instead of 85% of the MCD. With more conformal implant geometries the risk on moderate to severe fibrosis can substantially be reduced.

MISCELLANEOUS

33 oral

RENO: A European surveillance registry of coronary brachytherapy with the Novoste™ Beta-Cath™ System.

V. Coen 1, W. Sauerwein 2, R. Orecchia 3, P. Von Rottka 4, P. Coucke 4, M. Ehner 5, M. Donsbach 6, P. Urban 8, P. Levendag 7

1University Hospital Rotterdam/Daniel den Hoed Cancer Centre, The Netherlands

2Zentrum für Strahlungstherapie Universitätssklinikum Essen, Germany

3Department of Medicine Centro Cuore Columbus Milan, Italy

4Mueller Hospital München, Germany

5Department of Medicine C.H.U.V. Lausanne, Switzerland

6St. Georg Hospital Hamburg, Germany

7St. Johannes Hospital Dortmund, Germany

8Cardiovascular Department La Tour Hospital Meyrin-Geneva, Switzerland

Intravascular brachytherapy (IBT) has proven to be an effective mode of preventing restenosis following Percutaneous Coronary Intervention (PCI), but there are no data as yet concerning the application of VBT in routine clinical practice. Between April 1999 and September 2000, 1036 consecutive patients treated in 47 European centres with the Novostet Beta-Cath™ system were included in RENO, the single available registry of VBT. The 6 months follow-up data have so far been obtained for 546 patients. 785 (76.7%) patients were males, and mean age was 61.9±10.2 years. 248 (26.3%) had unstable angina and 238 (23.4%) were diabetics. 1030 (94.1%) target lesions were in native vessels and 65 (5.9%) in a bypass graft. 196 (17.9%) were de novo lesions, 46 (4.2%) restenotic and 850 (77.6%) in-stent restenosis. Mean estimated reference diameter was 3.0±0.5mm, and mean estimated lesion length was 19.2±2.0mm.

VBT was successful in 1035/1084 lesions (95.5%) and geometrical miss occurred for 67 (6.2%). A dose of 18.8±3.2 Gy was delivered at 2mm from the source axis using a 30mm (182 lesions) a 40 mm (869 lesions) or a 60 mm (42 lesions) source train. A pullback stepping manoeuvre was used for 167 (15.5%) procedures. The dwell time had to be fractionated due of ischaemia for 40 procedures (3.7%). A new stent was implanted for 327 (30%) lesions.

In-hospital MACE rate (Major Adverse Cardiac Events) was 20/1036 patients (1.9%). At discharge, aspirin and clopidogrel were usually given for at least 6 months. At 6 months follow-up MACE rate was 106/546 (19.4%). Angiographic follow-up was available for 121/546 patients (75.4%): non-occlusive restenosis in 18.6% and total occlusion in 5.7% of cases. A combined end-point for late (30-180 days) definite or suspected target vessel occlusion was reached in 36 (6.5%) patients. At 6-month follow-up, for 96 eligible patients treated with a pullback stepping procedure MACE rate was 32.3%. Angiographic follow-up was performed in 81 of eligible patients (85.3%): restenosis rate was 34.6%, including 12.3% late total occlusions. These data, derived from a large cohort of unselected consecutive patients, suggest that the good results of recent randomised controlled trials can be replicated in routine clinical practice.

34 oral

Long lesions treated using Sr/Y90 source trains, a sub-analysis of RENO: a European Surveillance Registry with the Novoste TM Beta-Cath TM system

A. Colombo, G. Stankovic, P. Serruys, T. Schiele, E. Eeckhout, S. Silber, R. Bonan, P. Urban

Centro Cuore Columbus, Milan, Italy

The RENO registry with the Novoste™ Beta-Cath™ system has been established to keep track of all patients undergoing Beta-Cath brachytherapy not suitable for inclusion in any Beta-Cath trial. From the total of 1036 patients included so far in this registry, brachytherapy was delivered with the pullback technique in 162 of these patients (15.6%) due to the lesion length.

This report is based on the acute and 6 month follow-up data of these 162 patients in whom 165 lesions (171 located in native coronary arteries and 14 in by-pass grafts) were treated with this technique (1.14 lesion/patient). Mean age was 61.8±10.9 years and 133 were male (82.1%). 36 patients (22.2%) had diabetes and 37 (22.8%) had unstable angina. 47 lesions were de novo, 10 were restenotic, and 126 were in-stent restenosis. Reference vessel size was 3.2±0.6 mm and mean lesion length was 32.7±8.19 mm.

Radiation treatment was performed utilizing a 30 mm (17.4% of lesions), 40 mm (17.1% of lesions), or 50 mm (4.9% of lesions) long source train, with a mean dwell time of 7.2±1.24 min delivering 18.9±3.0 Gy at 2 mm from the center of the source. Procedures were successful in 177 lesions (96.7%). Stents were implanted in 83 lesions (45.8%). Geometric miss was noticed in 9 lesions (4.9%). In-hospital outcome: two patients (1.2%) had myocardial infarction, and two patients (1.2%) had repeat PTCA. There were no deaths or CABG. 96 patients were eligible for 6-month follow-up. The overall incidence of MACEs (death, myocardial infarction and TVR, including in-hospital events) was 32.3%. Three patients died (3.1%), 4 patients (4.2%) suffered myocardial infarction, and 27 patients (28.1%) underwent repeat target vessel revascularization (23 had rePTCA and 4 had CABG). Angiographic follow-up was performed in 81 of eligible patients (85.3%). Angiographic restenosis rate was 34.6%, which includes an incidence of late total occlusions of 12.3%.

Conclusions: these preliminary results seem to support the fact that the pull-back technique can be safely performed with this beta delivery system. The follow-up events appear acceptable considering the length of the lesions treated and the high incidence of in-stent restenosis in the baseline population.

35 oral

High dose rate brachytherapy is a curative treatment for small invasive or in situ endobronchial carcinoma

F. Lorch 1, D. Spaeth 2, P. Scheid 3, P. Aletti 1, D. Peiffert 1

1Department of brachytherapy, 2Medical Oncology, Alexis Vautrin Cancer Institute, 3Pneumology, University Hospital, 54511 Vandoeuvre-Les-Nancy, France

Introduction: high dose rate brachytherapy (HDR) is an option for treatment of small invasive or in situ endobronchial carcinoma. This retrospective study analyses the results of 33 consecutive patients treated with curative intent by this technique in our institute and followed up more than one year. Material and methods: between July 1994 and October 1999, 34 tumours were treated by HDR alone with usual schedule delivering 6 fractions of 5 Gy prescribed at 1cm from the catheters over 3 to 6 weeks. In 31 patients, surgical treatment was excluded because of histologic consideration (in situ carcinoma), history of pneumonectomy or general contraindications. Two patients were treated because of positive margin after surgery. All the tumours were Tis-T1 N0. Most of the treatment used a spacer on the catheters. A dosimetry with optimization was performed for each patient and at each fraction.

Results: the locations of tumors were as follow: 2 tracheals, 4 main bronchias, 20 lobars, and 8 segmentals. One catheter was used for 15 cases, 2 for 12 cases, 3 for 6 cases and 4 for 1 case. The median follow-up was 15 months (range, 5-49 months). The local control (endoscopic and histologic) was 94% at 2 months and 80% at 6 months after the treatment. Local disease failure occurred in 9 patients (29%) at a median time of 9 months. Two patients developed metastasis. The 1-year and 2-year overall survival rate by Kaplan-Meier method were 78% and 57.5% respectively. The 1-year and 2-year specific survival rates were 93% and 66%. Acute complications included 1 pneumothorax, late effects were 6 infections and 12 bronchial stenoses. There were neither hemoptysis, nor lethal laryngitis.

Conclusion: on the basis of strict selection of patients, HDR is a curative treatment for small invasive or in situ endobronchial carcinoma. It allows high local control and survival rates without serious toxicity. Therefore, it offers a good alternative for treatment with curative intent in inoperable patients.

36 oral

Conformal endorectal high dose rate brachytherapy treatment of locally advanced and resectable rectal carcinoma using 3D treatment planning

T. Vuona, B.A. Molina, P. Fava, M.D.C. Evans, L. Souhami, E. Podgorsak

Department of Radiation Oncology Montreal University, Canada

Purpose: to develop a conformal endorectal brachytherapy technique, by combining 3D treatment planning and high dose rate brachytherapy, in order to achieve tumor downstaging in patients with locally advanced rectal cancer.

Material and methods: 45 patients with newly diagnosed resectable adenocarcinoma of the rectum (T2-4) were treated with preoperative high dose rate afterloading endorectal brachytherapy. Pre-treatment imaging included pelvic MRI and endoscopic rectal ultrasound. Tumors were circumferential in 13 patients, semi-circumferential in 28 patients and less than semi-